TNF and venous thromboembolism: Recent meta-analyses have shown that the risk of venous thromboembolism (VTE) may increase in patients with immune-mediated inflammatory diseases treated with JAK inhibitors compared to placebo or tumor necrosis factor inhibitors, although these findings did not reach statistical significance (Campanaro et al., 2023; Zhang et al., 2023).